Screener
Vera Therapeutics VERA Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Vera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The source filing: Vera Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:33 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-212143
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Net cash (used in) provided by investing activities | (137,816) | 15,317 |
| Cash flows from financing activities | ||
| Proceeds from exercise of stock options and employee stock purchase plan | 3,942 | 1,533 |
| Net cash provided by financing activities | 3,942 | 1,533 |
| Net decrease in cash and cash equivalents | (240,374) | (37,556) |
| Cash and cash equivalents, beginning of period | 354,725 | 92,646 |
| Cash and cash equivalents, end of period | $114,351 | $55,090 |
| Supplemental disclosure of cash flow information |
Item 1. Financial Statements
FAQ
- What is Vera Therapeutics's financing cash flow?
- Vera Therapeutics (VERA) reported financing cash flow of $3.94M in Q1 2026.
- How has Vera Therapeutics's financing cash flow changed year-over-year?
- Vera Therapeutics's financing cash flow increased by 157.1% year-over-year, from $1.53M to $3.94M.
- What is the long-term trend for Vera Therapeutics's financing cash flow?
- Over 4 years (2021 to 2025), Vera Therapeutics's financing cash flow has grown at a 54.7% compound annual growth rate (CAGR), from $53.88M to $308.9M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.
Ask your AI about Vera Therapeutics's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude